Phase I study of ganetespib and ziv-aflibercept in patients with advanced gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and sarco... by Meehan, R.S, Kummar, S, O'Sullivan Coyne, G, Zlott, J, Horneffer, Y, Juwara, L, Streicher, H, Sharon, E, Harris, P, Doroshow, J.H, Chen, A

Get full text

Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors by O'Sullivan Coyne, G, Chen, A.P, Kummar, S, Meehan, R.S, Collins, J, Zlott, J, Kelly, K, Lenz, H.J, Newman, E.M, Morgan, R, Juwara, L, Eiseman, J, Beumer, J.H, Tomaszewski, J, Doroshow, J

Get full text

Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E2 -independent mechanisms by Deasy, B.M, O’Sullivan-Coyne, G, O’Donovan, T.R, Mckenna, S.L, O’Sullivan, G.C

Get full text

Curcumin induces apoptosis-independent death in oesophageal cancer cells by O'Sullivan-Coyne, G, O'Sullivan, G C, O'Donovan, T R, Piwocka, K, McKenna, S L

Get full text

Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E 2-independent mechanisms by Deasy, B.M., O’Sullivan-Coyne, G., O’Donovan, T.R., Mckenna, S.L., O’Sullivan, G.C.

Get full text

49MO Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS) by Chen, A., Sharon, E., Van Tine, B.A., Moore, N., Foster, J., Glod, J., Hu, J.S., Rosenberger, C., O'Sullivan Coyne, G., Doroshow, J.

Get full text

466 - Phase I study of ganetespib and ziv-aflibercept in patients with advanced gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and... by Meehan, R.S., Kummar, S., O'Sullivan Coyne, G., Zlott, J., Horneffer, Y., Juwara, L., Streicher, H., Sharon, E., Harris, P., Doroshow, J.H., Chen, A.

Get full text

Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms by Deasy, B M, O'Sullivan-Coyne, G, O'Donovan, T R, McKenna, S L, O'Sullivan, G C

Get full text

Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy by Strauss, J., Rajan, A., Apolo, A., Lee, J.M., Thomas, A., Chen, A., Coyne, G. O’Sullivan, Madan, R., Bilusic, M., Karzai, F., Sater, H. Abdul, Redman, J., Gatti-Mays, M., Floudas, C., Marte, J., Cordes, L., Schlom, J., Gulley, J.

Get full text

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors by Do, Khanh T., O’Sullivan Coyne, Geraldine, Hays, John L., Supko, Jeffrey G., Liu, Stephen V., Beebe, Kristin, Neckers, Len, Trepel, Jane B., Lee, Min-Jung, Smyth, Tomoko, Gannon, Courtney, Hedglin, Jennifer, Muzikansky, Alona, Campos, Susana, Lyons, John, Ivy, Percy, Doroshow, James H., Chen, Alice P., Shapiro, Geoffrey I.

Get full text

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies by Herrick, William G, Kilpatrick, Casey L, Hollingshead, Melinda G, Esposito, Dominic, O'Sullivan Coyne, Geraldine, Gross, Andrea M, Johnson, Barry C, Chen, Alice P, Widemann, Brigitte C, Doroshow, James H, Parchment, Ralph E, Srivastava, Apurva K

Get full text